PepGen shares are trading lower after the company announced clinical data from the 5 mg/kg multiple ascending dose cohort of the ongoing Phase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1. Also, Wedbush lowered its price target on the stock from $9 to $5.